NEWS!!!!
Veritas Newsletter: Thank You for Subscribing
View this email in your browser
News Release:
Veritas (CSE: “VRT”) Appoints Marapharm (CSE: “MDM”) Director Mr. Yari Nieken
January 18, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, has announced appointment of Mr. Yari Nieken as a director of the company. Mr. Nieken replaces Dr. Dom Spina who sadly passed away in December of 2016.
Mr. Nieken has a wide range of public company and capital market experience. He is Founder and President of Foremost Capital Inc. an Exempt Market Dealer. He is currently a director of Marapharm Ventures Inc. and has served on the boards of several public and private issuers including PUF Ventures (President & CEO), Lexagene Holdings Inc. (Director), Duport Capital Ltd (Director) and has raised substantial capital in his career. He holds an MBA from the Sydney Graduate School of Management and a BA from the University of British Columbia. He was formerly an investment advisor at Union Securities Corp. and continues to be a registrant in good standing in the provinces of British Columbia, Alberta, and Ontario.
Veritas’ CEO, Dr. Franciosi, commented, “I would like to welcome Mr. Nieken to the Veritas team and I am looking forward to working with him. Mr. Nieken brings a great wealth of experience to the company, specifically in areas of capital markets, growth strategies, and marketing. With the scientific work progressing rapidly and having now secured the necessary financing, Mr. Nieken’s experience will be very valuable as Veritas prepares to embark on its next steps of its journey.”
Mr. Nieken commented, “I am extremely excited to be joining the Board of Directors at Veritas Pharma. I believe that Veritas Pharma is uniquely positioned for growth within a very exciting segment of the pharmaceutical industry, and I am committed to contributing to this growth to the best of my abilities.”
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging discovery and IP development company, committed to advancing the science behind medical cannabis. The company’s current R&D efforts are being conducted through its strategic partner, Cannevert Therapeutics Ltd. (“CTL”). The ultimate objectives of our R&D efforts are to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for real science to support medical marijuana claims.
About Cannevert Therapeutics Ltd.
CTL is a private company owned by a unique group of chemists, pharmacologists, and other medical science professionals. With offices located on the campus of the University of British Columbia, CTL has obtained permission from Health Canada to conduct research on cannabis strains. CTL has entered a funding agreement with Veritas where, upon advancing $1.5 million to CTL, Veritas will earn an 80% ownership interest in CTL. To date, Veritas has advanced $750,000 to CTL and holds contingent ownership of, but not the voting rights over, 40.5% of the issued and outstanding common shares of CTL. Veritas will not acquire full ownership rights, including voting rights, over any CTL common shares until the entire $1.5 million has been paid. CTL has also entered a licensing agreement with Veritas, licensing Veritas to market all products developed by CTL.
Veritas’ and CTL’s unique value proposition employs a whole plant methodology, using a low cost research and development model to help drive shareholder value and speed-to-market. The company’s commercial mission is to patent protect its IP (cultivars/ strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.
Veritas Pharma Inc. is a publicly traded company, which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.
For more information, please visit our website: veritaspharmainc.com
On behalf of the Board of Directors; Veritas Pharma Inc.
Dr. Lui Franciosi
Chief Executive Officer
Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com
Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: ir@veritaspharmainc.com
Website: www.veritaspharmainc.com
The CSE has not reviewed, nor approved or disapproved the content of this press release.
DISCLAIMER: Forward-Looking Information: This news release contains certain forward-looking information. All information, other than information regarding historic fact that addresses activities, events or developments that the Company believes, expects or anticipates will or may occur in the future is forward-looking information. The forward-looking information contained in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. With respect to the forward-looking information contained in this news release, the Company has made assumptions regarding, among other things, the results of the research and development activities, and the continued ability of the Company to raise additional financing. The forward-looking information contained in this news release is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from current expectations, including the any future changes to laws pertaining to the use of cannabis derived pharmaceuticals, prices and demand for cannabis derived pharmaceuticals, future currency and interest rates. Additionally, if the Company is unable to obtain additional financing, the Company may be required to curtail activities and/or liquidate its assets or the Company's creditors may seek to seize its assets. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable law, the Company disclaims any obligation to update or modify such forward-looking information, either because of new information, future events or for any other reason. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty therein. The CSE has not reviewed, nor approved or disapproved the contents of this press release.
Veritas Investor Summary
More on Veritas
Recent News Releases:
Veritas Pharma Enters into Agreement to Secure ACMPR License and Cannabis Growing Facility
Veritas Announces an Expansion to the Private Placement and Engages European Healthcare Capital
Veritas Announces Cannimed Ltd. As The New Supplier Of Cannabis Strains For Animal Studies
Veritas Pharma Inc. Exclusive Partner Qualifies For Non-Dilutive Grant – Update
Veritas Corporate Video
Veritas in Media
You are receiving this email because you opted into our newsletter on veritaspharma.com
Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list
DISCLAIMER: Forward-Looking Information: This news release contains certain forward-looking information. All information, other than information regarding historic fact that addresses activities, events or developments that the Company believes, expects or anticipates will or may occur in the future is forward-looking information. The forward-looking information contained in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. With respect to the forward-looking information contained in this news release, the Company has made assumptions regarding, among other things, the results of the research and development activities, and the continued ability of the Company to raise additional financing. The forward-looking information contained in this news release is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from current expectations, including the any future changes to laws pertaining to the use of cannabis derived pharmaceuticals, prices and demand for cannabis derived pharmaceuticals, future currency and interest rates. Additionally, if the Company is unable to obtain additional financing, the Company may be required to curtail activities and/or liquidate its assets or the Company’s creditors may seek to seize its assets. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable law, the Company disclaims any obligation to update or modify such forward-looking information, either because of new information, future events or for any other reason. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty therein. The CSE has not reviewed, nor approved or disapproved the contents of this press release.
Our mailing address is:
101 – 2386 East Mall
University of British Columbia
Vancouver, BC V6T 1Z3
Facebook
Website
LinkedIn
Copyright © 2016 Veritas Pharma Inc, All rights reserved.
Email Marketing Powered by MailChimp
